Altasciences invites you to an exclusive symposium on April 30th, from 1 p.m. to 5 p.m., at the MassBioHub, in Cambridge, MA.
This is a complimentary event, and registration is mandatory by filling out the form HERE.
Join our panel of experts as we explore a spectrum of topics, including the latest regulatory updates and effective strategies to navigate them. We’ll discuss the impact of the current financial landscape on various biotech companies, the optimal pathway for nonclinical gene therapy development, and how ethnobridging can significantly accelerate project timelines.
AGENDA:
- 1:00 p.m. to 1:10 p.m.: Introduction, Lisa Sanford, Vice President Business Development, Altasciences
- 1:10 p.m. to 1:45 p.m.: A Message from Chris Perkin, CEO, Altasciences
- 1:45 p.m. to 2:15 p.m.: Nonclinical Adeno-Associated Virus (AAV) Gene Therapy Development–Key Considerations for Study Design, Laboratory Endpoints, and Regulatory Guidance. Julie Forget, DESS Tox, DABT, Senior Director, Safety Assessment, Altasciences and Pierre Jolicoeur, PhD, Scientific Director, Laboratory Sciences, Altasciences.
- 2:15 p.m. to 3:00 p.m.: Conducting Clinical Trial in Canada – A Strategic Regulatory Pathway? Eryn Corriveau, MSc, BSc, Senior Director, Drug Development and Regulatory Strategy, Altasciences.
- 3:00 p.m. to 3:45 p.m.: Navigating Critical Crossroads in Early Clinical Development. Dr. Mel Affrime, PharmD, President and Chief Scientific Officer, Altasciences, Dr. David Nguyen, MD, MBA, General Manager and Medical Director, Altasciences, Dr. Christopher Banfield, PhD, CB Pharma Consulting Services, Dr. Shivraj Sohur, MD, PhD, Vice President, Neurology Clinical Development, Ono Pharma USA INC.
- 4:15 p.m. to 4:25 p.m.: Closing Remarks, Lisa Sanford, Vice President Business Development, Altasciences
- 4:25 p.m.: Networking and cocktails
Abstracts and registration HERE.